Monitoring the treatment of patients treated by anti-TNFα
Anti-TNFαs are therapeutic treatments widely prescribed to treat more than 50,000 patients affected by various chronic inflammatory pathologies. They consist of biomarkers capable of binding TNFα and blocking the action of the TNFα that is responsible for the inflammatory state.
Infliximab, Adalimumab, and Etanercept are anti-TNFα biologics recommended for treating pathologies such as rheumatoid arthritis, Crohn’s disease, ankylosing spondylarthritis, and psoriasis . These biotherapies represent a cost of some €1 billion in France.
Whatever the anti-TNF-α, some authors have demonstrated the appearance of anti-drug neutralizing antibodies (ADAb = Anti-Drug Antibodies) among patients presenting therapeutic resistance (20% to 60% of treated patients). This presence of ADAb appears as a precursor to potential clinical deterioration (therapeutic escape).
The LISA TRACKER Premium kits are the first CE marked kits allowing simultaneous dosage of three parameters within three hours of reaction from a serum sample:
- Circulating TNFα is one of the main markers involved in the inflammatory process. TNFα is a complex predictive marker that may lead to new areas of research.
- Prescribed anti-TNF-α (Infliximab, Adalimumab, Etanercept, Certolizumab-pegol, golimumab) to optimize dosage consistent with the presence or absence of ADAb.
- The presence of antibodies directed against the medication (ADAb), of which authors have reported the presence among patients experiencing loss of drug efficacy.
These kits allow clinicians to monitor the patient’s trough plasma levels of these three parameters over time. The combination of these three parameters allows them to anticipate, optimize, and better manage the patient’s treatment.
MultimediaBiotherapies managemnet in IBDs Interview Prof. Roblin (Gastro-entérologue – CHU Saint Etienne)
Paul S, Del Tedesco E, Rinaudo-Gaujous M, Rinaldi L, Moreau A, Genin C, Phélip J-M, Roblin X. Impact of infliximab dosage and anti-infliximab antibodies in the therapeutic optimization of MICI patients that are non-responders to infliximab therapy. JFHOD 2012, 15-18 March 2012, Paris, France.
Instructions for use